<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243814</url>
  </required_header>
  <id_info>
    <org_study_id>N08-429</org_study_id>
    <nct_id>NCT01243814</nct_id>
  </id_info>
  <brief_title>A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study of the Relative Efficacy of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry DeGroot, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry DeGroot, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the therapeutic effect of single intra-articular injection of hyaluronate with a
      single intra-articular injection of normal saline (placebo) for osteoarthritis of the ankle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, prospective, double-blind (blinded observer) , saline
      solution-controlled, parallel experimental design. The study device is SUPARTZ (Seikagaku
      Corporation, Tokyo, Japan) a brand of sodium hyaluronate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOFAS score, difference from mean at 6 weeks and 12 weeks</measure>
    <time_frame>6 weeks 12 weeks</time_frame>
    <description>American Orthopaedic Foot and Ankle score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>supartz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active intervention arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intervention arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronate intra-articular injection</intervention_name>
    <description>joint injection in ankle with hyaluronate</description>
    <arm_group_label>supartz</arm_group_label>
    <other_name>Supartz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <description>joint injection with saline solution for placebo</description>
    <arm_group_label>saline injection</arm_group_label>
    <other_name>saline injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible, subjects had to be at least 18 years old, not pregnant, and have pain
             and osteoarthritis of the ankle of at least stage 2 on the Kellgren and Lawrence
             scale.

          -  Their AOFAS score had to be 90 points or less out of a possible 100 points.

          -  Eligible subjects had to be willing to discontinue all pain medications and NSAIDs
             other than the rescue pain medications provided in the study.

        Exclusion Criteria:

          -  Persons with systemic inflammatory condition or infection of the ankle or nearby soft
             tissues,

          -  an injection of steroid or surgery on the involved joint within 6 months,

          -  local cellulitis, rash, skin condition

          -  diabetic or neuropathic Charcot arthropathy,

          -  significant vascular insufficiency,

          -  current treatment with anticoagulants,

          -  lower extremity pain syndromes, sciatica, sprains, plantar fasciitis,

          -  significant ankle instability or malalignment,

          -  any known allergy to any of the components of either injection, known or suspected
             allergy to birds or bird products,

          -  disabling degenerative joint disease of the ipsilateral hip, knee or foot were
             ineligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry DeGroot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newton-Wellesley Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The office of Dr. Henry DeGroot</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>March 19, 2012</last_update_submitted>
  <last_update_submitted_qc>March 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Henry DeGroot, M.D.</name_title>
    <organization>Henry DeGroot</organization>
  </responsible_party>
  <keyword>hyaluronate</keyword>
  <keyword>hyaluronic acid</keyword>
  <keyword>viscosupplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

